Evaluation of serum Angiopoietin-like protein 2 (ANGPTL-2), Angiopoietin-like protein 8 (ANGPTL-8), and high-sensitivity C-reactive protein (hs-CRP) levels in patients with gestational diabetes mellitus and normoglycemic pregnant women.

Abstract

OBJECTIVE\nIn the present study, we aimed to investigate the role of the fasting serum levels of Anjiopoetın 2 - like protein (ANGPTL2), Anjiopoetın 8-like protein (ANGPTL8), and high-sensitivity C-reactive protein (hs-CRP) in the etiopathogenesis of gestational diabetes mellitus (GDM), and analyze the relationships between insulin resistance parameters.\n\n\nMATERIAL AND METHOD\nThe 90 individuals admitted to İzmir Katip Celebi University Hospital Internal Medicine, Endocrinology and Obstetrics, and gynecology outpatient clinic were included in the study of similar ages and similar demographic characteristics. Forty-five women with diet-controlled GDM and 45 women with normoglycemic pregnancy were enrolled. ANGPTL-2, ANGPTL-8, hs-CRP, creatinine, ALT, GGT, lipid profile, HBA1c(%), and serum insülin, c-peptide levels were studied in the fasting serum samples of research groups. All individuals had 75-g OGTT testing. GDM screening was performed at 24-28 weeks gestation. Exclusion criteria were as follows: Age <18\u2009years or >40\u2009years, pregestational diabetes (type 1 or 2), drug or alcohol abuse, thyroid dysfunction, Hepatitis B, and other infectious diseases (Herpes virus, Streptococcus B carriers, Chlamydia and Candida), Thalassemia carriers or other significant medical conditions, the use of any medication that interferes with lipid or glucose metabolism that would affect glucose regulation.\n\n\nRESULT\nForty-five women with GDM and for the control group, 45 women with normoglycemic pregnant women were identified. The mean gestational age was 30.7 (18-38) for GDM and 29.6 (24-39) for the control group. Serum ANGPTL-8 (GDM =19.5\u2009±\u200993 Control = 0.73\u2009±\u20093.78 p\u2009=\u2009<.001). There was a statistically significant difference between the case and control groups for serum ANGPTL-8 levels. Serum ANGPTL-2 (GDM =19.9\u2009±\u200923.1 Control = 26.0\u2009±\u200923.4 p\u2009=\u2009.105) and serum hs-CRP(GDM =106\u2009±\u200965.1 Control =98.2\u2009±\u200987.3 p\u2009=\u2009.768). There was no statistically significant difference between the case and control groups for serum ANGPTL-2 and hsCRP levels. Serum ANGPTL8 levels were positively correlated with FPG (r\u2009=\u20090.391, p\u2009=\u2009<.001), FPI (r\u2009=\u20090.212, p\u2009=\u2009.045), 1-h PPG (r\u2009=\u20090.514, p = <.001), 2-h PPG (r\u2009=\u20090.502, p = <.001), HOMA-IR) score (r\u2009=\u20090.310, p\u2009=\u2009.003), TG (r\u2009=\u20090.245, p\u2009=\u2009.020); they were not except for BMI, hs-CRP levels and ANGPTL2 levels.\n\n\nCONCLUSIONS\nANGPTL8 levels were significantly higher in GDM than in healthy control group. ANGPTL2 levels and hs-CRP levels were similar to the healthy control group. Elevated serum ANGPTL8 levels were correlated significantly with insulin resistance parameters, the main component of GDM pathophysiology. Our data showed that ANGPTL8 could be a new biomarker for diagnosing GDM.